Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia

References

• American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Inchai J, Pothirat C, Liwsrisakun C, et al. Ventilator-associated pneumonia: epidemiology and prognostic factors of 30-day mortality. Jpn J Infect Dis. 2015;68:181–186.
   PubMed Web of Science ®Google Scholar
• Styers D, Sheehan DJ, Hogan P, et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob. 2006;5:2.
   PubMedGoogle Scholar
• Antimicrobial resistance surveillance in Europe 2014 [Internet]. Solna (Sweden): European Centre for Disease Prevention and Control [Internet]; 2015 [cited 2016 May 24]. Available from: www.ecdc.europa.eu
   Google Scholar
• Chastre J, Blasi F, Masterton RG, et al. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20:19–36.
   PubMed Web of Science ®Google Scholar
• Welte T, Pletz MW. Antimicrobial treatment of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents. 2010 Nov;36:391–400.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011 Jan;55(1):405–410.
   PubMed Web of Science ®Google Scholar
• Howden BP, Johnson PD, Ward PB, et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006;50:3039–3047.
   PubMed Web of Science ®Google Scholar
• Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204:340–347.
   PubMed Web of Science ®Google Scholar
• Masterton R, Cornaglia G, Courvalin P, et al. The clinical positioning of telavancin in Europe. Int J Antimicrob Agents. 2015;45:213–220.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EPAR summary for the public. Vibativ, telavancin. European Medicines Agency. 2011 Jun [cited 2014 May 6]. Available from: http://www.ema.europa.eu/docs/enGB/documentlibrary/EPAR-Summary for the public/human/001240/WC500115429.pdf
   Google Scholar
• Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother. 2008 Aug;9:2197–2207.
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:1127–1134.
   PubMed Web of Science ®Google Scholar
• Lunde CS, Hartouni SR, Janc JW, et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009;53:3375–3383.
   PubMed Web of Science ®Google Scholar
• Bambeke V. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol. 2004;4:471–78.
   PubMed Web of Science ®Google Scholar
• Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49:195–201.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent against Gram-positive bacteria. Antimicrob Agents Chemother. 2004;48:3043–3050.
   PubMed Web of Science ®Google Scholar
• Wong SL, Barriere SL, Kitt MM, et al. Multiple dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008;62:780–783.
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Wong SL, Shaw JP, et al. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010;30:806–811.
   PubMed Web of Science ®Google Scholar
• Samara E, Shaw JP, Barriere SL, et al. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother. 2012;56:2067–2073.
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Noel AR, Tomaselli S, et al. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2011;55:867–73.
   PubMed Web of Science ®Google Scholar
• Smith K, Gemmell CG, Lang S. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. Eur J Clin Microbiol Infect Dis. 2013;32:1327–1332.
   PubMed Web of Science ®Google Scholar
• CLSI (Clinical and Laboratory Standards Institute) [Internet]. Wayne: CLSI [cited 2016 Jan 12]. Available from: Available from: http://clsi.org/wp-content/uploads/sites/14/2016/01/M100S26_Correction_Notice_20160110_Web-1.pdf
   Google Scholar
• Gotfried MH, Shaw JP, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008;52:92–97.
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Gotfried M, Barriere S, et al. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008 Jul;52:2300–2304.
   PubMed Web of Science ®Google Scholar
• Odenholt I, Lowdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin- susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother. 2007;51:3311–3316.
   PubMed Web of Science ®Google Scholar
• VIBATIV (telavancin) prescribing information. Theravance Biopharma Antibiotics. 2014 Dec [cited 2015 Jan 15]. Available from: http://www.vibativ.com
   Google Scholar
• Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:1177–1184.
   PubMed Web of Science ®Google Scholar
• Hoiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–332.
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Mermel LA. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother. 2009;53:3166–9.
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:462–5.
   PubMed Web of Science ®Google Scholar
• Darouiche RO, Mansouri MD, Schneidkraut MJ. Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. Antimicrob Agents Chemother. 2009;53:2626–2628.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother. 2010 Dec;54:5115–9.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Skinner R, et al. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother. 2008 Jan;61:169–172.
   PubMed Web of Science ®Google Scholar
• Thabit AK, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of telavancin against methicillin-susceptible and -resistant Staphylococcus aureus with and without prior vancomycin exposure. Antimicrob Agents Chemother. 2015 Oct;19(60):222–228.
   Google Scholar
• Lin G, Pankuch GA, Ednie LM, et al. Antistaphylococcal activity of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother. 2010;54:2201–2205.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Jones RN. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). Int J Antimicrob Agents. 2010 Oct;36:374–379.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Farrell DJ, et al. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010). Diagn Microbiol Infect Dis. 2011;71:93–97.
   PubMed Web of Science ®Google Scholar
• Putnam SD, Sader HS, Moet GJ, et al. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis. 2010;67:359–368.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis. 2015;61(Suppl 2):S58–S68.
   PubMed Web of Science ®Google Scholar
• Ross JE, Mendes RE, Jones RN. Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method. J Clin Microbiol. 2014;52:3399–3401.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, et al. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis. 2015;81:275–9.
   PubMed Web of Science ®Google Scholar
• Leonard S, Yong YG, Zolotarev M, et al. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents. 2011;37:558–561.
   PubMed Web of Science ®Google Scholar
• Krause KM, Blais J, Lewis SR, et al. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2012;74:429–431.
   PubMed Web of Science ®Google Scholar
• Finegold SM, Bolanos M, Sumannen PH, et al. In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates. AntimicrobAgents Chemother. 2009;53:3996–4001.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of the new semisynthetic glycopeptides telavancin (TD-6424), vancomycin, daptomycin, linezolid and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother. 2004;48:2149–2152.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. In: 24th informational supplement. Wayne (PA): CLSI; 2014. p. M100–S24.
   Google Scholar
• Nichol KA, Adam HJ, Laing N, et al. Activity of telavancin against gram-positive cocci from CANWARD 2007–2013 using previously established and revised CLSI guidelines (abstract C-826). 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014 September 5–9; Washington, DC.
   Google Scholar
• Farrell DJ, Krause KM, Benton BM. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. Diagn Microbiol Infect Dis. 2011;69:275–279.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Farrell DJ, et al. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram- positive clinical pathogens from five continents. Antimicrob Agents Chemother. 2012;56:3999–4004.
   PubMed Web of Science ®Google Scholar
• Smith JR, Barber KE, Hallesy J, et al. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother. 2015;59:5529–5534.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Sader HS, et al. Telavancin activity against Gram- positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother. 2010;65:2396–2404.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al.; ATTAIN Study Group. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011 Jan;1(52):31–40.
   Web of Science ®Google Scholar
• Corey GR, Rubinstein E, Stryjewski ME, et al. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. 2015;60:787–796.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Stryjewski ME, Barriere SL. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator associated pneumonia. Infect Drug Resist. 2014;7:129–135.
   PubMed Web of Science ®Google Scholar
• Siempos II, Vardakas KZ, Kyriakopoulos CE, et al. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock. 2010;33:590–601.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Barriere SL, Rubinstein E, et al. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents. 2013;42:367–369.
   PubMed Web of Science ®Google Scholar
• Torres A, Rubinstein E, Corey GR, et al. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother. 2014;69:1119–26.
   PubMed Web of Science ®Google Scholar
• Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014;58:2030–2037.
   PubMed Web of Science ®Google Scholar
• Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015;71:707–714.
   PubMed Web of Science ®Google Scholar
• Polyzos KA, Mavros MN, Vardakas KZ, et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One. 2012;7(8):e 41870.
   Web of Science ®Google Scholar
• Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004;44:689–95.
   PubMed Web of Science ®Google Scholar
• Wenzler E, Rodvold KA. Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions. Clin Infect Dis. 2015;61:S38–47.
   PubMed Web of Science ®Google Scholar
• Clinigen Group Inc. Clinigen reports pan European lifting of MA suspension for Vibativ. Press release. 2014 Mar 18 [cited 2015 Jan 12]. Available from: http://www.clinigengroup.com/media/news/clinigen-reports-pan-european-lifting-of-ma-suspension-vibativr
   Google Scholar
• Chan C, Hardin TC, Smart JI. A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections. Future Microbiol. 2015;10:1325–1338.
   PubMed Web of Science ®Google Scholar